Core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50
= 1.1 μ
M). Represses RUNX1/CBFβ
-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ
. Reduces leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. Also a Tat antagonist; inhibits HIV-1 replication in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF� interaction.
Cunningham et al.
The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter.
Cupelli et al.
RUNX1/AML1: a central player in hematopoiesis.
Okuda et al.
Int. J. Hematol., 2001;74:252
The citations listed below are publications that use Tocris products. Selected citations for Ro 5-3335 include:
Showing Results 1 - 1 of 1